To develop a non-invasive biomarker framework specifically for early detection and classification of Alzheimer's Disease (AD) using lactylation-related molecular signatures.
Key Findings:
The LDS model demonstrated high diagnostic performance, correlating with Braak stage and Mini-Mental State Examination (MMSE) scores, highlighting its significance compared to existing biomarkers.
LDS scores increased progressively from normal controls to aMCI and AD patients.
Combining LDS with plasma p-tau181 and p-tau217 improved detection of AD and amyloid-tau positive individuals.
Interpretation:
The study highlights the potential of lactylation as a novel biomarker for AD, linking metabolic and epigenetic alterations to disease progression.
Limitations:
The study primarily focuses on lactylation without exploring other potential biomarkers, which may limit the understanding of AD's complexity.
Further validation in larger, diverse cohorts is needed to confirm findings and enhance generalizability.
Conclusion:
LDS represents a promising, interpretable blood-based tool for early detection and stratification of Alzheimer's Disease, with significant potential implications for clinical practice.
